RALEIGH – GeneVentiv Therapeutics, a Triangle-area pre-clinical gene therapy company, has been awarded a $250,000 Strategic Research Loan (SRL) from the North Carolina Biotechnology Center (NCBC).

The loan will enable the company to conduct pre-clinical studies, said Damon Race, CEO of GeneVentiv Therapeutics, in a statement.

GeneVentiv is focused on therapies for blood diseases and disorders.  Last year, the company was granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for its lead program, GENV HEM.

Now, the company will use the loan funds to prepare for an investigational new drug (IND) application and human clinical trials, Race noted in the statement.

“This funding from the NC Biotechnology Center adds to our momentum,” said Race.